O’Melveny Represents Jenscare Scientific in Its Hong Kong IPO10월 10, 2022
FOR IMMEDIATE RELEASE
HONG KONG—OCTOBER 10, 2022—O’Melveny recently represented Jenscare Scientific Co., Ltd. (9877.HK) in its initial public offering and listing of shares on the Main Board of the Hong Kong Stock Exchange. O’Melveny advised Jenscare on both U.S. and Hong Kong laws and drafted the prospectus. This marks O’Melveny’s 12th Chapter 18A Hong Kong IPO completed for biotech companies, further solidifying the firm’s leading position in this field.
Founded in Ningbo, Zhejiang in 2011, Jenscare is a leading medical device company dedicated to the development of interventional products for the treatment of structural heart diseases. It self-developed a series of innovative treatment solutions targeting different types of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases and heart failure. Its core product, LuX-Valve, is expected to become the world’s first transcatheter tricuspid valve replacement system approved for commercialization.
China International Capital Corporation Hong Kong Securities Limited and Citigroup Global Markets Asia Limited acted as the joint sponsors and overall coordinators for this transaction.
The O’Melveny team for this transaction was led by corporate partners Ke Zhu, Ke Geng, and Ye Sun, with assistance from counsel Wendy Kan and Yazhe Liu, associates Sean Sy, Amy Sung, Rita Deng, Stella Yang, and Fan Wu, legal consultants Zixie Zhu and Yirong Du, senior legal assistant Cherry Ma, and trainee solicitor Ann Marie Choy. Partners Robert Plesnarski, Luc Moritz, counsel Billy Abbott and Dawn Lim provided tax and U.S. legal opinion related advice.
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com, hear what our lawyers, staff and clients have to say in Our DNA video series, or learn more in our firm at-a-glance, annual report, and on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
O’Melveny & Myers LLP
+1 213 430 8024
O’Melveny & Myers LLP
+86 21 2307 7000